Santaris grabs $30M in third round venture cash

Denmark's Santaris Pharma has banked $30 million from its latest venture round. Gilde Healthcare Partners put up much of that money with BankInvest, Novo, LD, Forbion Capital Partners, Global Life Science Venture, Sunstone Capital, Seventure, Omega, Innovation Capital and members of the company's board and management joining in.

Santaris has been studying RNA antagonist drug candidates based on its LNA chemistry. In 2008 the company said it expects to advance its SPC2996 compound, an RNA antagonist of Bcl-2, into Phase II clinical trials in chronic lymphocytic leukemia and B-cell lymphoma and initiate phase I volunteer studies of two new RNA antagonists for metabolic disorders. 

- check out the release for more info

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.